Related Experiment Videos

Antithrombotic therapy in patients with coronary artery disease and with type 2 diabetes mellitus

Serdar Farhan1, Thomas Höchtl, Alexandra Kautzky-Willer

  • 1Third Department of Cardiology and Emergency Medicine, Wilhelminen Hospital, Vienna, Austria. serdar.farhan@wienkav.at

Wiener Medizinische Wochenschrift (1946)
|March 16, 2010
PubMed

Insights

Diabetic patients with acute coronary syndrome (ACS) benefit most from prasugrel and certain antithrombins like enoxaparin or bivalirudin. These treatments significantly reduce adverse cardiovascular events in this high-risk population.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Diabetes mellitus (DM) significantly increases cardiovascular disease (CVD) risk, with patients facing a 2-4 fold higher incidence.
  • Coronary artery disease (CAD) and acute coronary syndrome (ACS) are major complications for individuals with DM.
  • Effective therapeutic strategies are crucial for managing ACS in diabetic patients.

Purpose of the Study:

  • To evaluate the efficacy of various antiplatelet agents and antithrombins in diabetic patients with ACS.
  • To compare the effectiveness of different treatment options in reducing adverse clinical events in this specific population.
  • To identify optimal pharmacological interventions for diabetic individuals experiencing ACS.

Main Methods:

  • Review of clinical trial data and subgroup analyses focusing on diabetic patients with ACS.
  • Comparison of outcomes for oral antiplatelet agents including prasugrel.
  • Assessment of glycoprotein IIb-IIIa receptor inhibitors and antithrombins (e.g., UFH, enoxaparin, fondaparinux, bivalirudin) in ACS management.

Main Results:

  • Prasugrel demonstrated the highest efficacy among oral antiplatelet agents for diabetic patients with ACS.
  • Glycoprotein IIb-IIIa receptor inhibitors showed greater reduction in adverse events in diabetic subjects undergoing PCI compared to non-diabetics.
  • Enoxaparin and bivalirudin proved superior to unfractionated heparin (UFH) in both ST-elevation MI (STEMI) and non-ST elevation MI (NSTEMI) diabetic subgroups.

Conclusions:

  • Prasugrel is a highly effective oral antiplatelet agent for diabetic patients with ACS.
  • Specific antithrombins, namely enoxaparin and bivalirudin, offer superior outcomes compared to UFH in managing MI in diabetic populations.
  • Treatment choices should be tailored to optimize cardiovascular event reduction in diabetic patients with ACS.

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...